

Contents

About the authors	xii
Foreword	xiv
Reviewers	xv
Acknowledgements	xvi
About this resource	xvii
Guide to text	xix

PART 1

Introduction to pharmacology 1

1 Drugs and medicines 1

Kirsten Small, Roslyn Donnellan-Fernandez

Introduction 2

1.1 Drugs and medicines 2

Characteristics of drugs, 2

1.2 Drug discovery and development 4

Where drugs come from, 4

Drugs sourced from natural or traditional remedies, 5

Standards and government regulation, 10

Stages of drug development, 10

1.3 Drug names and classifications 13

Drug names, 13

Chemical names, 13

Proprietary (trade or brand) names, 17

Drug classifications, 17

1.4 Drug information 18

Important drug information, 18

What users of medications want to know, 18

Official sources, pharmacopoeias and formularies, 18

Semi-official sources, 19

Other drug information sources, 20

2 Clinical, ethical and legal foundations of pharmacotherapy 23

Roslyn Donnellan-Fernandez, Kirsten Small

2.1 Clinical aspects of pharmacotherapy 24

Quality use of medicines, 24

Modifying drug usage over time, 26

Roles of health professionals in QUM, 29

Drug prescriptions and formulations, 31

Teaching prescribing, 36

2.2 Ethical aspects of pharmacotherapy 36

Human rights, the basis for bioethics, 36

2.3 Legal aspects of pharmacotherapy 39

International law, 39

Regulation of drugs in Australia, 40

Regulation of drugs in New Zealand, 43

PART 2

Principles of pharmacology 48

3 Molecular drug targets and pharmacodynamics 48

Maryam Bazargan, Kirsten Small, Roslyn Donnellan-Fernandez

Introduction 49

3.1 Drug specificity, selectivity, and affinity 49

3.2 Molecular drug targets 50

Transporters, 50

Ion channels, 50

Enzymes, 50

Receptors, 50

Second messengers, 51

Desensitisation and receptor turnover, 53

3.3 Pharmacodynamics 54

Drug target interactions, 54

Antagonists, 55

Allosteric effects, 56

Concentration–response relationship, 56

Potency, 57

Efficacy, 57

4 Drug absorption, distribution, metabolism and excretion 61

Maryam Bazargan, Kirsten Small

Introduction 62

4.1 Drug absorption 62

Absorption across biological membranes, 63

Passive diffusion, 63

Carrier-mediated transport, 63

Variables affecting drug absorption, 63

Routes of drug administration, 65

Bioavailability, 68

Absorption of drugs during pregnancy, 69

4.2 Distribution 69

Plasma protein binding, 69

Hypoalbuminaemia, 70

Tissue binding, 70

Tissue-specific barriers to drug distribution, 70

Drug distribution in pregnancy, 70


Drug distribution in the fetus, 71

4.3 Drug elimination (metabolism and excretion) 72

Drug metabolism, 72

Variability in drug metabolism, 73

4.4 Excretion of drugs and drug metabolites	75	Disorders of menstruation, 102	
Hepatic uptake and biliary excretion, 75		Endometriosis, 102	
Renal excretion, 76		Polycystic ovary syndrome, 103	
Pulmonary excretion, 76		Hirsutism, 103	
4.5 Pharmacokinetics during pregnancy and early life	77	7.2 Female infertility	103
Renal excretion during pregnancy, 77		Preconception, 103	
Pharmacokinetic development during early life, 77		7.3 Pregnancy	106
5 Pharmacokinetics and dosing regimen	79	Maternal adaptations, 106	
<i>Maryam Bazargan, Kirsten Small</i>		Drug use in pregnancy, 106	
Introduction	80	Teratogenesis: causing abnormal fetal development, 107	
5.1 Plasma concentration–time profile of a drug	80	Database for prescribing medicines in pregnancy, 109	
5.2 Key pharmacokinetic concept: Clearance	80	7.4 Common conditions in pregnancy	110
Hepatic clearance, 82		Nausea and vomiting in pregnancy (NVP), 110	
Renal clearance, 83		Gastro-oesophageal reflux, 114	
The importance of clearance, 83		Constipation, 116	
5.3 Key pharmacokinetic concept: Volume of distribution	83	Candidiasis, 118	
5.4 Key pharmacokinetic concept: Half-life	84	Rh (D) immunoglobulin, 119	
Determinants of half-life, 85		7.5 Complementary and alternative medicines (CAMs)	120
5.5 Dosage measurements and calculations	86	Aromatherapy, 120	
Measurement systems, 86		Herbal medicines, 122	
Conventional notations, 87		Homeopathics in pregnancy, 122	
6 Adverse drug reactions and drug interactions	89	Conclusion	123
<i>Maryam Bazargan, Kirsten Small</i>		8 Labour and birth	126
Introduction	90	<i>Clare Davison, Roslyn Donnellan-Fernandez</i>	
6.1 Adverse drug reactions	90	Introduction	127
Risk factors for developing an adverse drug reaction, 90		8.1 Physiology of labour and birth	127
Incidence of adverse drug reactions, 91		8.2 Overview of drugs used during labour	128
Classification of adverse drug reactions, 91		8.3 Uterotonics	128
Drug allergy, 91		Oxytocics, 128	
6.2 Drug interactions	92	Ergot alkaloids, 130	
Frequency of drug interactions, 92		Prostaglandins, 131	
Classification of drug interactions, 93		Antifibrinolytic and haemostatic agents, 132	
Absorption, 93		Tocolytics, 133	
Distribution, 94		8.4 The pathophysiology of pain	133
Metabolism, 94		The experience of pain, 135	
Excretion, 95		The gate control theory, 135	
Drug interactions with nutrients and CAMs, 95		Non-pharmacological pain management: sterile water injections, 137	
PART 3		8.5 Pharmacological relief of pain	138
Pharmacology across the childbearing continuum	98	Paracetamol, 138	
7 Pregnancy	98	Opioids, 138	
<i>Clare Davison, Roslyn Donnellan-Fernandez</i>		Clinical considerations when using opiates during labour and birth, 140	
7.1 Overview of the female reproductive system controls and hormones	99	Morphine, 141	
The 'puberty clock', 99		Fentanyl, 144	
The menstrual cycle, 99		8.6 Inhalation agents	144
		Nitrous oxide, 145	
		Methoxyflurane, 146	



8.7 Local anaesthetic	147	Hormones and lactation, 186	
Chemistry and dissociation of local anaesthetic drugs, 147		Lactation promoters and inhibitors, 187	
Esters and amides, 147		Passage of drugs into breast milk, 188	
Mechanism of action, 147		Passive diffusion, 189	
Pharmacokinetics, 148		Active transport, 190	
Use of a vasoconstrictor, 149		10.3 Pharmacokinetics in infants	190
Parenterals, 149		Drug risk in breastfed infants, 191	
Central nerve block: epidural anaesthesia, 150		Potential drug interactions and adverse effects between prescribed medications and breast milk, 191	
Dermatome assessment, 151		Drug interactions with prescription medication, 192	
Epidural (extradural) anaesthesia, 152		Adverse effects of recreational drugs while breastfeeding, 192	
Patient controlled epidural analgesia, 152		Medication for which there is limited evidence of long-term effects, 196	
Central nerve block: spinal (subarachnoid) anaesthesia, 152		Drugs and breastfeeding guidelines, 196	
Combined spinal/epidural analgesia, 153		10.4 Online clinical protocols and classification systems	197
Adverse drug reactions, 153		Classification systems for the safety of drugs in lactation, 197	
8.8 General anaesthetic	153	Management and treatment: inflammatory mastitis and bacterial mastitis, 199	
Inhalation anaesthetics, 153		Complementary medicines and breastfeeding recommendations, 200	
IV anaesthetic agents, 154		Principles of safe prescribing to neonates, 203	
Ultrashort-acting barbiturates, 155		Conclusion	207
Conclusion	156	11 Vaccinations in pregnancy and recommended schedule for newborns	211
9 The postnatal period	159	<i>Michelle Gray, Roslyn Donnellan-Fernandez, Kirsten Small</i>	
<i>Clare Davison, Roslyn Donnellan-Fernandez</i>		Introduction	213
Introduction	160	11.1 The immune system	213
9.1 Analgesia	160	Innate immunity, 213	
Paracetamol, 161		Adaptive immunity, 213	
Non-steroidal anti-inflammatory drugs (NSAIDs), 161		Primary immune response and immunological memory, 215	
Opioids, 162		Secondary immune response, 215	
9.2 Infection, bladder and bowel care	163	Active vs artificially acquired immunity, 216	
Perineal trauma and repair, 163		11.2 Vaccines given during pregnancy	219
Bladder and bowel care, 163		Types of vaccine, 219	
9.3 Postnatal contraception	164	Whole-cell vaccines, 220	
Contraception for women, 164		Subunit vaccines, 223	
Hormone components of COC formulations, 166		New vaccine type: nucleic acid vaccines, 225	
Counselling points, 170		11.3 Vaccine schedules	226
Oral COC formulations, 170		Primary series, 226	
Emergency contraception, 173		Boosters, 226	
Non-oral hormonal contraception, 174		Annual influenza vaccine, 226	
Long-acting reversible contraceptives, 174		Herd immunity, 227	
Non-drug contraceptive methods, 176		11.4 Clinical considerations	227
Failure of contraception, 177		Vaccine cold chain management, 227	
9.4 Postnatal mental health	180	Vaccine administration technique, 227	
9.5 Complementary and alternative medicine	180	Using body landmarks to administer intramuscular vaccines, 228	
Conclusion	181		
10 The newborn and lactation	183		
<i>Roslyn Donnellan-Fernandez, Clare Davison</i>			
Introduction	185		
10.1 Use of medicines while breastfeeding	185		
Safe drug therapy during lactation, 185			
10.2 Pharmacology and breastfeeding	186		
Anatomical overview and physiology – mammary glands, 186			

- Administering a vaccine into the vastus lateralis (anterolateral thigh), 229
- Administering a vaccine into the deltoid, 229
- Reporting vaccinations to national registers, 230
- Vaccine side effects, 230

Conclusion: The future of vaccines 230

PART 4

Pharmacology for special considerations 234

12 Infection and sepsis – maternal and neonatal 234

Michelle Gray, Roslyn Donnellan-Fernandez

- Introduction 235
- 12.1 Aetiology of infection 235
- 12.2 Pathogens 236
 - Bacteria, 237
 - Viruses, 239
 - Fungi, 239
 - Parasites, 239
 - Algae, 240
- 12.3 Infections during pregnancy 240
 - Bacterial infection, 240
 - Viral infection, 242
 - Parasitic infection, 243
- 12.4 Treatments 244
 - Antibacterial medications, 244
 - Antivirals, 247
 - Antifungals, 247
 - Parasitic infection treatment, 248
- 12.5 The microbiome and complementary and alternative medicine (CAM) considerations 248
 - CAM considerations, 248
- Conclusion 250

13 Diabetes in pregnancy and its management 254

Maryam Bazargan, Kirsten Small, Roslyn Donnellan-Fernandez

- Introduction 255
- 13.1 Pancreatic hormones and diabetes mellitus 256
 - Insulin from the pancreas, 256
 - Diabetes mellitus, 256
 - Blood glucose monitoring, 260
- 13.2 Management of gestational diabetes 261
 - Drugs for gestational diabetes, 261
 - Insulin, 261
 - Insulin formulations, 261
 - Insulin administration, 263
- 13.3 Management of type 2 diabetes 265
 - Drugs for type 2 diabetes, 265

- Metformin, 265
- OHAs not used in pregnancy, 266
- Hypoglycaemia, 268

14 The thyroid 272

Kirsten Small, Maryam Bazargan

- Introduction 273
- 14.1 Thyroid hormones 273
 - Synthesis, storage and secretion, 273
 - Regulation, 274
 - Mechanism of thyroid hormone actions, 277
- 14.2 Thyroid physiology and pregnancy 277
 - Pharmacotherapy of thyroid disorders, 277
 - Hypothyroidism, 278
 - Hyperthyroidism (thyrotoxicosis), 281
 - Iodine/iodide, 283
 - Radioactive iodine, 284

15 Drugs affecting the heart, vascular system and blood volume 286


Maryam Bazargan, Kirsten Small

- 15.1 Introduction: The heart 287
 - Control by the autonomic nervous system, 287
 - The cardiac conduction system, 289
 - The vascular system, 291
 - The renin–angiotensin–aldosterone system, 291
 - The sympathetic nervous system, 292
- 15.2 Hypertension in pregnancy 295
 - Drug therapy for hypertension in pregnancy, 296
 - Calcium channel blockers, 297
 - β -adrenoceptor antagonists, 299
 - Non-selective α_1 - and β -adrenoceptor antagonists, 299
 - Direct-acting vasodilators, 303
 - Centrally acting adrenergic inhibitors, 303

16 Blood and blood clotting 306

Kirsten Small, Maryam Bazargan

- Introduction 307
- 16.1 Blood composition 307
 - Blood cell production, 307
- 16.2 Physiological changes in the haemopoietic system in pregnancy and the puerperium 309
 - Anaemia, 309
 - Iron deficiency and iron deficiency anaemia, 310
 - Folic acid and vitamin B12, 311
- 16.3 Blood clotting 312
 - The haemostatic mechanism, 312
- 16.4 Physiological changes in the coagulation system in pregnancy and the puerperium 313
 - Thromboembolic disorders and pregnancy, 313
 - Placental function disorders and thrombophilias, 313
 - Anticoagulation and pregnancy, 314
 - Bleeding disorders and pregnancy, 315



16.5 Anticoagulant drugs	315	18.4 Bronchodilator drugs	348
Fondaparinux: Antithrombin-III-dependent anticoagulant, 320		β -adrenoceptor agonists, 348	
16.6 Antiplatelet agents	321	Methylxanthines, 350	
Aspirin, 321		Anticholinergics, 352	
16.7 Haemostatic and antifibrinolytic drugs	321	18.5 Prophylactic antiasthma drugs (preventers)	352
Tranexamic acid, 321		Corticosteroids, 352	
Protamine (reverses heparin's action), 322		Mechanism of action, 352	
Vitamin K (reverses warfarin's action), 322		Systemic administration and adverse effects, 353	
17 Premature labour and birth	324	Glucocorticoid resistance, 353	
Michelle Gray, Roslyn Donnellan Fernandez		18.6 Other drug groups	354
Introduction	325	Leukotriene-receptor antagonists (LTRAs), 354	
17.1 Prematurity definitions and causes	325	New drugs for asthma, 354	
Premature labour, 325		Drugs to be used with caution for pregnant and postpartum women with asthma, 354	
Premature birth, 325		18.7 Therapies and management of asthma in pregnancy	355
Causes of prematurity, 326		Combination therapy, 355	
17.2 Diagnosis of premature labour	327	Suboptimal therapy, 355	
Signs and symptoms of premature labour, 327		Stepwise management, 355	
A transvaginal ultrasound scan of the cervix in the mid-trimester, 327		Chronic asthma, 355	
Assessments that assist in diagnosis, 328		Acute asthma, 355	
Transfer of the mother and fetus in utero, 329		Asthma action plans, 355	
17.3 Medications in the management of preterm labour and premature birth	329	19 Mental health	359
Antibiotic therapy, 329		Kirsten Small, Maryam Bazargan, Roslyn Donnellan-Fernandez	
Corticosteroids, 329		Introduction: Mental health and illness	360
Uterotonics and tocolytics, 329		Mental illness in the childbearing year, 360	
Calcium channel blockers, 329		Mental illness in Indigenous populations, 361	
Second-line tocolytics – Cydooxygenase inhibitors, 331		19.1 Pathophysiology of mental health disorders	361
Atosiban (Tractocile), 333		Monoamine neurotransmitters, 362	
Progesterone, 333		19.2 Approaches to therapy	362
17.4 Complementary and alternative therapies	333	Non-drug therapy, 362	
Dietary supplementation, 334		Pharmacotherapy, 363	
Conclusion	334	Informed decision making in mental illness, 364	
18 Asthma	337	Discontinuation of therapy and rebound effects, 364	
Kirsten Small, Michelle Gray		19.3 Anxiety	365
Introduction: The respiratory system, asthma and its treatment	338	Anxiety in the childbearing year, 365	
18.1 Control of respiration	338	Benzodiazepines, 365	
Regulation of the glands and musculature of the respiratory tract, 338		19.4 Depression	367
18.2 Asthma – An overview	339	Depression in the childbearing year, 367	
Pathophysiology of asthma, 340		Antidepressant drugs, 367	
Asthma in pregnancy, 341		Antidepressant drug therapy: clinical aspects, 368	
Asthma and lactation, 342		Tricyclic antidepressants, 369	
Drugs used in asthma, 342		Monoamine oxidase inhibitor antidepressants, 369	
18.3 Considerations for drug delivery to the airways	344	Selective serotonin reuptake inhibitors, 369	
Aerosols, 344		Serotonin noradrenaline reuptake inhibitors, 369	
Inhaled drugs, 345		Adverse drug reactions of antidepressants, 370	
		Serotonin syndrome, 370	
		Drug interactions, 371	
		19.5 Posttraumatic stress disorder	371
		Bipolar affective disorder, 372	
		Lithium: the antimanic drug, 372	

19.6 Postpartum psychosis	374		
Antipsychotic agents, 374			
Drug interactions, 376			
20 Epilepsy	379		
<i>Kirsten Small, Maryam Bazargan, Roslyn Donnellan-Fernandez</i>			
Introduction	380		
Classification of seizures, 380			
Triggers to seizures, 383			
20.1 Antiepileptic drug therapy	383		
Clinical aspects, 383			
Monotherapy and subsequent therapy, 384			
Choice of antiepileptic drug, 384			
Drug-resistant epilepsy, 384			
Status epilepticus, 384			
Medication adherence and therapeutic drug monitoring, 384			
Discontinuing antiepileptic therapy, 384			
Principles of epilepsy management for women in their reproductive years, 385			
AEDs and teratogenesis, 385			
AEDs and neurobehavioural effects for the infant, 385			
Contraception, 386			
Pregnancy and epilepsy, 386			
The puerperium and epilepsy, 386			
Eclampsia, 387			
20.2 Antiepileptic drugs	387		
The ideal antiepileptic drug, 387			
General considerations, 388			
Antiepileptic hypersensitivity syndrome, 389			
Drug interactions, 389			
20.3 Mechanisms of action of currently used antiepileptics	389		
Antiepileptics that enhance GABA inhibition, 389			
Antiepileptics that inhibit sodium channel function, 390			
Antiepileptics that act by other mechanisms, 393			
Conclusion	394		
21 Drugs of dependence	397		
<i>Kirsten Small, Roslyn Donnellan-Fernandez, Maryam Bazargan</i>			
Introduction	398		
21.1 Drug abuse and misuse	398		
Drug dependence, 398			
Withdrawal syndromes, 399			
Patterns of drug abuse in Australia, 399			
Patterns of drug abuse in New Zealand, 399			
Drug abuse during pregnancy and breastfeeding, 399			
21.2 Central nervous system stimulants	400		
Caffeine and the xanthine alkaloids, 400			
Nicotine and tobacco smoking, 401			
Amphetamines, 402			
21.3 Dependence on opioids	404		
Opioid abuse and dependence, 404			
Opioid dependence and pregnancy, 404			
Managing women with pharmacological dependence on opioids, 405			
Methadone or buprenorphine maintenance, 405			
Acute overdosage, 406			
Analgesia for women with opioid abuse disorders, 406			
21.4 Alcohol	406		
Ethanol (ethyl alcohol, 'alcohol'), 407			
Pharmacological mechanisms and actions of ethanol, 407			
Hangover and alcohol withdrawal syndrome, 409			
21.5 Cannabis drugs (marijuana, hashish)	409		
Preparations and active constituents, 409			
Administration and pharmacokinetics, 409			
Mechanism and pharmacological effects, 409			
Medical uses of cannabinoids, 410			
22 Role of the midwife	413		
<i>Roslyn Donnellan-Fernandez, Clare Davison, Michelle Gray, Maryam Bazargan, Kirsten Small</i>			
Introduction	414		
Scope of practice, 415			
International prescribing context, 415			
22.1 Governance of midwifery prescribing	415		
Midwifery prescriptive authority in New Zealand, 415			
Midwifery prescriptive authority in Australia, 416			
22.2 Educational preparation for prescribing	417		
Australian requirements for endorsement for scheduled medicines as a midwife, 418			
22.3 Legislation and regulations impacting prescribing and medication management	419		
Criminal law, 419			
Civil law, 419			
Commonwealth legislation, 419			
State or territory legislation, 419			
Regulation of midwifery prescribing, 419			
Australian midwifery framework, 419			
22.4 Quality and safety	422		
Quality use of medicines, 422			
Prescribing practice: ensuring quality and safety, 422			
Health profession prescribing pathway, 422			
NPS medicinewise prescribing competencies framework, 422			
Person-centred use of medicines, 423			
National safety and quality standards: Medication management, 432			
22.5 Role of the midwife in prescribing	433		
Consultation, referral and collaboration, 433			



Pharmaceutical benefits scheme prescribing by midwives, 434	Professional indemnity insurance, 437	
22.6 Additional professional obligations for midwives	Complaints, 438	
Continuing professional development, 437	Conclusion	439
	Index	443